Use of ursodeoxycholic acid in liver diseases

被引:57
|
作者
Kumar, D [1 ]
Tandon, RK [1 ]
机构
[1] All India Inst Med Sci, Dept Gastroenterol, New Delhi 110029, India
关键词
bile acid; cholestasis; liver diseases; ursodeoxycholic acid;
D O I
10.1046/j.1440-1746.2001.02376.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ursodeoxycholic acid is currently the only established drug for the treatment of chronic cholestatic liver diseases. It has cytoprotective, anti-apoptotic, membrane stabilizing, anti-oxidative and immunomodulatory effects. Prolonged administration of ursodeoxycholic acid in patients with primary biliary cirrhosis (PBC) is associated with survival benefit and a delaying of liver transplantation. There is evidence that it might even prevent progression of the histologic stage of PBC. It also has a beneficial effect on primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, liver disease associated with cystic fibrosis, chronic graft versus host disease, total parenteral nutrition associated cholestasis and various pediatric cholestatic liver diseases. In the present review the current knowledge about the mechanisms of the action and role of ursodeoxycholic acid in the treatment of various liver diseases has been discussed. (C) 2001 Blackwell Science Asia Pty Ltd.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 50 条
  • [11] URSODEOXYCHOLIC ACID FOR CHOLESTATIC DISEASES
    KITANI, K
    LANCET, 1988, 2 (8601): : 49 - 49
  • [12] Ursodeoxycholic acid in hepatobiliary diseases
    Kim, Hyuk
    Yoo, Jeong-Ju
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2024, 67 (09): : 603 - 611
  • [13] Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review
    Reardon, Jillian
    Hussaini, Trana
    Alsahafi, Majid
    Azalgara, Vladimir Marquez
    Erb, Siegfried R.
    Partovi, Nilufar
    Yoshida, Eric M.
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2016, 4 (03) : 192 - 205
  • [14] THE EFFECT OF URSODEOXYCHOLIC ACID IN CHRONIC LIVER-DISEASES - A PILOT-STUDY
    DAVID, R
    KURTZ, W
    STROHM, WD
    LEUSCHNER, U
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1985, 23 (09): : 420 - 420
  • [15] URSODEOXYCHOLIC ACID USE AND OUTCOMES OF CORONAVIRUS 2019 IN PATIENTS WITH LIVER DISEASE
    John, Binu V.
    Bastaich, Dustin R.
    Moon, Andrew
    Webb, Gwilym
    Ferreira, Raphaella D.
    Chin, Allison M.
    Kaplan, David E.
    Taddei, Tamar H.
    Serper, Marina
    Mahmud, Nadim
    Doshi, Akash
    Deng, Yangyang
    Chao, Hann-Hsiang
    Dahman, Bassam
    HEPATOLOGY, 2022, 76 : S557 - S558
  • [16] USE OF URSODEOXYCHOLIC ACID (UDCA) IN CHILDREN WITH CHOLESTATIC LIVER-DISEASE
    PARADIS, K
    ELARAB, N
    YOUSEF, I
    LACAILLE, F
    SCHREIBER, R
    LEVY, E
    RASQUINWEBER, A
    HEPATOLOGY, 1993, 18 (04) : A301 - A301
  • [17] Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases
    Halilbasic, Emina
    Steinacher, Daniel
    Trauner, Michael
    DIGESTIVE DISEASES, 2017, 35 (03) : 288 - 292
  • [18] Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
    Trauner, M
    Graziadei, IW
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (08) : 979 - 995
  • [19] Effect of long-term therapy of cholestatic liver diseases with ursodeoxycholic acid.
    Miloshevski, M
    Serafimoski, V
    Trajanovski, D
    Vasilevski, V
    Joksimovic, N
    GASTROENTEROLOGY, 2000, 118 (04) : A1470 - A1470
  • [20] Use of Ursodeoxycholic Acid and the Risk of Long COVID in Patients With Steatotic Liver Disease
    Woo, Jieun
    Kim, Gi-Ae
    Bea, Sungho
    Choi, Ahhyung
    Jung, Kyungyeon
    Kim, Won
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 210 - 210